user avatar
Geoff Oxnard MD
@geoff_oxnard
Drug & diagnostic developer | Thoracic oncology, Boston Medical Center | Husband, father of 4, splitter of wood | Opinions my own
Boston, MA
Joined September 2016
Posts
  • Pinned
    user avatar
    Fantastic energy this week presenting preliminary findings from our SOLARA trial of BH-30643 in Boston. Please check out the poster which is now on the BHT pipeline website! Study enrolling full steam ahead with a focus on on-target resistance and TKI-naive #EGFR-mutant NSCLC.
  • user avatar
    Oncologists, what's more HOPEFUL than: - caring for a tragically young pt w refractory cancer... - achieving response to investigational tx... - referring him/her back to local doc... - and then stumbling upon him/her years later on TWITTER, now married and thriving?!?
  • user avatar
  • user avatar
    Here come 4th generation EGFR inhibitors! New allosteric EGFR inhibitor from Pasi Janne, Nathanial Gray & Michael Eck @DanaFarber, synergistic with osimertinib, just out @CD_AACR. @EGFRResisters #LCSM cancerdiscovery.aacrjournals.org/content/early/…
  • user avatar
    Super exciting to work with @genentech on this creative analysis in @NatureMedicine of IMpower150 demonstrating the power of ctDNA monitoring to predict outcome on chemoIO: nature.com/articles/s4159…
  • user avatar
    More cool work from the Janne lab @DanaFarber figuring out the vulnerabilities of dormant EGFR-mutant NSCLC on TKI. Inhibiting MEK plus YAP/TEAD tips these surviving cells into apoptosis! cell.com/cancer-cell/fu…
  • user avatar
    Nice paper from @MDAndersonNews showing that levels of tumor DNA shed are prognostic. Let's start using liquid biopsies as quantitative tools not just positive/negative! @CCR_AACR clincancerres.aacrjournals.org/content/early/…
  • user avatar
    For EGFR resistance, remember to biopsy and test for MET amp! SAVANNAH trial of osimertinib / savolitinib now enrolling globally: thelancet.com/journals/lanon… @LeciaSequist
  • user avatar
    So cool to see EGFR C797S being targeted @AACR ! Proud to support a new paradigm of real-time ctDNA response assessment in first-in-human trials - congrats to @ElaineShumMD & @BlueprintMeds:
  • user avatar
    Two vaccinated! 💉🩹 The younger two will have to wait. Thank you @challiance! ❤️
  • user avatar
    Our new editorial @CCR_AACR: "Effective cancer genotyping -- many means to one end" clincancerres.aacrjournals.org/content/early/…. A joy to write with Dr. Catherine Meador @BrighamWomens, soon a fellow @DanaFarber! Many tools available so ALL patients can receive effective cancer genotyping.
  • user avatar
    Does testing error underlie liquid biopsy discordance? "Bake-off" from @AstraZeneca suggests that, in the wild world of plasma NGS assays, technical factors impact assay variability more than we realize: ascopubs.org/doi/10.1200/PO…
  • user avatar
    1/10 I left #ASCO23 last week feeling INSPIRED about the pace of progress & discovery for cancer patients! I'm excited about2⃣ precision oncology themes from the meeting, and it seems others in the oncology community share my excitement:
  • user avatar
    Super excited for our #ASCO23 ctDNA evidence! 🧬ctDNA monitoring w @BrunaPellini @genentech & @NIVokes @Regeneron 🧬ctDNA tumor fraction w @ChristianRolfo @flatironhealth & @LungMAP 🧬ctDNA fusions w @pashtoonkasi 🧬ctDNA HRRm w @pfizer See you there! foundationmedicine.com//press-release…